Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle(TM) Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)

Stock Information for Oncotelic Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oncotelic Therapeutics Inc

Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature
Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discovery
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
OTCQB Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th
OTCQB Virtual Investor Conference Agenda Announced for August 5 & 6
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
Oncotelic Announces Peer-Reviewed Validation of Deciparticle(TM) Platform Supporting Clinical Development of Sapu003

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.